IDiyas

For the Inventor, By the Inventor

Lansdale, PA, United States of America

William F Hoffman

USPTO Granted Patents = 61

Average Co-Inventor Count = 3.0

ph-index = 20

Forward Citations = 1,285(Granted Patents)


Inventors with similar research interests:


Location History:

  • Chalfont, PA (US) (1978 - 1979)
  • Hope Valley, RI (US) (1983)
  • Winchester, IN (US) (1988)
  • Rahway, NJ (US) (1999)
  • Lansdale, PA (US) (1978 - 2008)

Company Filing History:

goldMedal59 out of 4,770 
 
Merck + Co., Inc.
 patents
silverMedal1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1978-2008

Loading Chart...
61 patents (USPTO):Explore Patents
1. 7378411 - Substituted thienopyrimidinones as a mitotic kinesin inhibitor (2008-05-27),
2. 7348440 - Mitotic kinesin inhibitors (2008-03-25),
3. 7329762 - Prodrugs of mitotic kinesin inhibitors (2008-02-12),
4. 7262187 - Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor (2007-08-28),
5. 7262186 - Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor (2007-08-28),
6. 7186723 - Tyrosine kinase inhibitors (2007-03-06),
7. 7109204 - Tyrosine kinase inhibitors (2006-09-19),
8. 7060705 - Mitotic kinesin inhibitors (2006-06-13),
9. 6794393 - Tyrosine kinase inhibitors (2004-09-21),
10. 6306874 - Tyrosine kinase inhibitors (2001-10-23),
11. 6228871 - Angiogenesis inhibitors (2001-05-08),
12. 6211184 - Integrin antagonists (2001-04-03),
13. 5981546 - Integrin antagonists (1999-11-09),
14. 5972975 - Substituted 2-aminopyridines as inhibitors of nitric oxide synthase (1999-10-26),
15. 5929120 - Guainidino, formamidino, amino and related compounds for inhibiting (1999-07-27),

Title: William F. Hoffman: Innovator in Cancer Treatment

Introduction

William F. Hoffman, based in Lansdale, PA, is an esteemed inventor with an impressive portfolio of 59 patents. His contributions to the field of pharmaceuticals, particularly in cancer treatment, showcase his commitment to advancing medical science.

Latest Patents

Two of Hoffman's latest inventions involve novel compounds aimed at treating cellular proliferative diseases. The first patent, "Substituted thienopyrimidinones as a mitotic kinesin inhibitor," pertains to thienopyrimidinone compounds effective in inhibiting KSP kinesin activity and treating related disorders in mammals, including cancer. The second patent, titled "Mitotic kinesin inhibitors," describes dihydropyrrole compounds that similarly address the same cellular proliferative diseases and disorders associated with KSP kinesin activity.

Career Highlights

Hoffman is currently associated with Merck & Company, Inc., a leading global healthcare company known for its innovative research and development. His work significantly contributes to the field of oncology, aiming to explore new avenues for effective cancer treatment.

Collaborations

Throughout his career, Hoffman has collaborated with notable peers, including George D. Hartman and Ta J. Lee. Together, they have worked on groundbreaking research, further enhancing the impact of their collective expertise in medical innovation.

Conclusion

William F. Hoffman's extensive patent portfolio and his enduring collaborations underscore his vital role in the pharmaceutical industry. His innovations continue to pave the way for new therapeutic options in the fight against cancer, marking him as a prominent figure in the field of medical inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…